急性心肌梗死患者早期应用阿托伐他汀强化治疗的临床效果及安全性分析

目的探讨急性心肌梗死（AMI）患者早期应用阿托伐他汀强化治疗的临床效果及安全性分析。方法将118例AMI患者分入对照组与观察组，58例对照组患者人院后12h内给予阿托伐他汀20mg／d，60例观察组患者入院后12h内接受阿托伐他汀40mg／d强化治疗，疗程4周。比较两组心血管事件发生率、血清超敏C反应蛋白（hs—CRP）、血脂及不良反应发生率。结果观察组心肌梗死、心绞痛发生率显著低于对照组（P〈0．05）；观察组三酰甘油、总胆固醇、低密度脂蛋白胆固醇和hs—CRP显著低于对照组（P〈0．05）；两组不良反应发生率比较差异无统计学意义（P〉0．05）。结论AMI患者早期应用阿托伐他汀强化治疗可减少心血管事件发生率，降低血脂及血清炎症因子，且不增加不良反应。

Clinical effect and security analysis of early intensive therapy with Atorvastatin in acute myocardial infaction

Objective To explore the effect and security analysis of early intensive therapy with Atorvastatin in acute myocardial infaction （AMI）. Methods 118 cases with AMI were divided into control group and experience group. 58 cases of control group were given conventional-dose Atorvastatin （20 rag/d） and 60 patients of experience group received intensive therapy Atorvatation （40 mg/d）within 12 hours after admission. A course of treatment was 4 weeks. The cardio- vascular events, hs-CRP, blood lipid and adverse rate were compared between two groups. Results The occurrence of AMI and angina in experience group were much lower than those in control group （P 〈 0.05）; compared with control group, serum TG, TC, LDL-C and hs-CRP after treatment in experience group decreased significantly （P 〈 0.05）; there was no significant difference of adverse rate between the two groups （P 〉 0.05）. Conclusion Early intensive therapy with Atorvastatin for AMI greatly decrease the cardiovascular events, blood lipid and inflammatory factors without increasing the adverse reaction.